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A B S T R A C T
Hepatitis C virus (HCV) is a globally disseminated human pathogen for which no vaccine is currently available.
HCV is highly diverse genetically and can be classiﬁed into 7 genotypes and multiple sub-types. Due to this
antigenic variation, the induction of cross-reactive and at the same time neutralizing antibodies is a challenge in
vaccine production. Here we report the analysis of immunogenicity of recombinant HCV envelope glycoproteins
from genotypes 1a, 1b and 2a, with a Flag tag inserted in the hypervariable region 1 of E2. This modiﬁcation did
not aﬀect protein expression or conformation or its capacity to bind the crucial virus entry factor, CD81.
Importantly, in immunogenicity studies on mice, the puriﬁed E2-Flag mutants elicited high-titer, cross-reactive
antibodies that were able to neutralize HCV infectious particles from two genotypes tested (1a and 2a). These
ﬁndings indicate that E1E2-Flag envelope glycoproteins could be important immunogen candidates for vaccine
aiming to induce broad HCV-neutralizing responses.
1. Introduction
Hepatitis C virus (HCV), a member of the Flaviviridae family, is a
globally disseminated human pathogen causing liver disease, such as
cirrhosis and hepatocellular carcinoma (Alter and Seeﬀ, 2000). Glob-
ally, in 2015, an estimated 71 million people were living with chronic
HCV infection (WHO, 2017). Despite the recent development of highly
eﬀective direct-acting antivirals (DAA) (González-Grande et al., 2016),
the infection remains a major health problem worldwide. This is due to
the limited availability and high cost of new therapies, low infection
awareness and high probability of reinfection in high-risk groups
(Baumert et al., 2014). Therefore, an eﬀective prophylactic and/or
therapeutic vaccine is still needed to control the virus globally. One of
the major obstacles for vaccine development is the extreme genetic
variability of HCV, driven by its escape from immune pressure.
The HCV envelope glycoproteins E1 and E2 play a crucial role in the
complex process of virus entry into the host cell. They are a primary
target for the antiviral adaptive immune response and therefore are
important immunogen candidates for the design and development of
vaccines against HCV (Wang et al., 2011). The current knowledge of
E1E2 structure and functions comes from numerous biochemical,
molecular and immunological studies and was recently improved by
obtaining the crystal structure of E2 core (Khan et al., 2014; Kong et al.,
2013). However, the genetic diversity and the complex structure of the
heterodimer formed by E1 and E2 makes them a very diﬃcult research
target.
Here we show the construction, puriﬁcation and broad functional
and immunological evaluation of E1E2-based antigens derived from
three diﬀerent HCV genotypes. The E1E2 recombinant proteins were
tagged with the Flag tag, for the facilitation of protein isolation and
puriﬁcation. Numerous recombinant Flag-tagged viral proteins have
been previously described and eﬃciently puriﬁed by various groups.
These include the gp120 of simian immunodeﬁciency virus (SIV) (Laird
and Desrosiers, 2007), ORF virus envelope proteins (Tan et al., 2009)
and the VP1 protein from foot-and-mouth disease virus (FMDV)
(Lawrence et al., 2013). Furthermore, the Flag tag has been successfully
used in the study of HCV for the puriﬁcation of cell cultured viral
particles (HCVcc) (Merz et al., 2011; Prentoe and Bukh, 2011).
We previously identiﬁed a site within the hypervariable region 1
(HVR-1) of the genotype 1a HCV strain H77 glycoprotein E2 where a
small insertion of 5–6 amino acids was tolerated without a negative
eﬀect on the protein structure and function (Rychlowska et al., 2011).
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Based on that data, in the present report we constructed and analyzed
three E1E2 mutants with the Flag octapeptide inserted at amino acid
position 409 in the HVR-1 of E2. We show that such an insertion is well
tolerated in three diﬀerent HCV genotypes (1a, 1b and 2a). We also
demonstrate that Flag insertion in this site does not hinder protein
expression, proper conformation of E2 and the activity of the glyco-
protein – E1E2 dimer formation and CD81 binding. Moreover, we ex-
amined the immunogenic properties of E1E2-Flag and found that im-
munization of mice with aﬃnity puriﬁed recombinant Flag-tagged
proteins induced anti-E2 antibodies capable of neutralizing cell cul-
tured HCV (HCVcc). These results establish the E1E2-Flag as potential
vaccine immunogens as well as tools for molecular and antigenic stu-
dies.
2. Results
2.1. Construction and expression of E1E2-Flag glycoproteins
In this study, we have constructed Flag-tag modiﬁed E2 glycopro-
teins derived from the two HCV genotypes most prevalent in Europe
and North America – 1a and 1b (Petruzziello et al., 2016), as well as
from genotype 2a, from which the ﬁrst clone replicating eﬃciently in
cell culture was isolated (Wakita et al., 2005; Zhong et al., 2005; Kato
et al., 2006) (Fig. 1. A.). The sequences used for this study were pre-
viously described by (Tarr et al., 2007), who ampliﬁed E1E2 from pa-
tient-derived sera and cloned them into the pcDNA3 expression vector,
under the control of the human cytomegalovirus (CMV) promoter. The
Flag DYKDDDDK octapeptide tag was introduced at position 409 in E2,
immediately preceding the conserved Q410 glutamine residue.
The E1E2-Flag proteins were transiently expressed in 293T cells and
the expression was examined by Western blotting and in situ im-
munostaining. The recombinant proteins were recognized by both the
anti-E2 mAb AP33, as well as by the anti-Flag mAb M2 (Fig. 1. B.). E2
proteins were of expected molecular weight of 62 kDa and the expres-
sion level was similar to the wild type E2, indicating that the addition of
the tag did not aﬀect the eﬃciency of protein synthesis. Im-
munohistochemical staining of 293T cells after transfection was per-
formed in parallel to Western blotting in order to visualize the ex-
pression of the E2 proteins directly in cells. The detection of
immunostained E1E2 wt and Flag from genotype 1a is shown on Fig. 1.
C. Similarly, when using an anti-E2 mAb positive signal was observed in
cells expressing both unmodiﬁed and tagged E1E2, while anti-Flag mAb
recognized exclusively the Flag tagged proteins and these results were
consistent for all three genotypes. Eﬃcient cell immunostaining with
anti-Flag mAb suggested that the Flag epitope was exposed on the
surface of recombinant HCV E2 glycoproteins and could be used for
further puriﬁcation purposes.
2.2. Aﬃnity puriﬁcation of E1E2-Flag heterodimers
It has been previously described that HCV E1 and E2 proteins as-
semble into non-covalent heterodimer (Castelli et al., 2017; Dubuisson
et al., 1994; Freedman et al., 2017). Ideally, the insertion of an aﬃnity
tag in either E1 or E2 should not interfere in this process and should
allow the eﬃcient puriﬁcation of functional E1E2 heterodimer with
correct conformation.
Agarose coupled to the M2 anti-Flag antibody was used as aﬃnity
resin to purify E1E2-Flag heterodimers from the lysates of transfected
293T cells. Proteins were expressed transiently for 48 h and puriﬁed
from cell lysates. To optimize the elution process, two diﬀerent methods
were used – a competition with the 3x Flag peptide and a low pH buﬀer
elution. We observed signiﬁcantly higher eﬃciency of E1E2-Flag elu-
tion using glycine buﬀer pH 2.7, which together with its cost eﬀec-
tiveness was the reason why this method was chosen for further ex-
periments. In the optimized elution procedure, the low pH in the eluted
fractions was immediately neutralized by Tris-HCl buﬀer pH 8.8.
Consistently with other reports (Meertens et al., 2006; Tscherne et al.,
2006), we have observed that short incubation in low pH followed by a
return to neutral pH did not result in precipitation or denaturation of
HCV glycoproteins. Following analysis of protein content and con-
centration, selected elution fractions were pooled and concentrated 10x
by ultraﬁltration.
We have estimated the puriﬁcation eﬃciency of E1E2-Flag after
transfection of 293T cells as 15 µg from 5 × 106 cells growing in sta-
tionary cultures. Protein concentration was estimated by Bradford assay
and the purity was veriﬁed on a Coomassie-stained 10% SDS-PAGE gel
and Western blotting. The same puriﬁcation procedure was used for all
three genotypes and an example for the puriﬁcation of gt1a E1E2-Flag
is shown on Fig. 2.
2.3. Analysis of E1E2 heterodimer formation
As mentioned before, correctly folded and functional intracellular
E1 and E2 proteins form a non-covalent heterodimer. In order to in-
vestigate the ability of E2-Flag to bind its partner glycoprotein E1,
radioimmunoprecipitation assay (RIPA) was performed. The anti-E2
mAb AP33 was used to precipitate the putative complexes from the
lysates of transfected 293T cells. To diﬀerentiate between precipitated
covalently bound protein aggregates and co-precipitated non-covalent
E1E2 heterodimers the proteins were analyzed by SDS-PAGE under
reducing and non-reducing conditions (Fig. 3. A.). As seen on the non-
reducing gel, monomeric E1 and E2 can be detected apart from a higher
molecular weight, b-mercaptoethanol-resistant multimers. Such mono-
meric forms indicate that at least a part of E1 and E2-Flag are able to
associate into functional non-covalent heterodimers. For glycoprotein
E1 multiple bands could be detected, most probably representing dif-
ferent glycosylation states of the protein, as observed by others in
earlier studies (Dubuisson et al., 2000). These results were further
conﬁrmed using anti-Flag antibody for IP. As expected, the M2 mAb co-
precipitated E1 together with E2 from the Flag mutants exclusively
(data not shown). Concluding, insertion of the Flag epitope did not
inﬂuence the heterodimerisation process of E1 and E2 HCV glycopro-
teins expressed transiently in HEK 293T cells.
2.4. E1E2-Flag proteins bind to HCV receptor CD81
As a next step, we investigated the ability of the E1E2-Flag proteins
to bind the HCV receptor CD81. CD81 is one of the essential entry re-
ceptors and blocking E1E2 interaction with CD81 neutralizes HCV in-
fection in vitro (Fénéant et al., 2014). The regions in E2 and CD81
responsible for the interaction have been mapped (Drummer et al.,
2006) and CD81 binding is often used as a functional “quality control”
assay for recombinant HCV glycoproteins (Heile et al., 2000). Here, the
assay was based on puriﬁed recombinant large extracellular loop (LEL)
of human CD81 protein, fused to GST. Immobilized GST-hCD81-LEL
was used as bait in pull-down assay to bind E1E2 proteins from cell
lysates (Fig. 3. B.). As a control, GST alone was used as bait. Re-
combinant CD81, but not GST alone, was able to pull down detectable
amounts of all the HCV E1E2 variants but with diﬀerent eﬃciency.
Results indicate that the addition of the Flag epitope did not disrupt the
CD81 binding site on E2.
2.5. The addition of the Flag epitope does not aﬀect the folding and
conformational epitopes of glycoprotein E2
To analyze the inﬂuence of the insertion of Flag epitope in the HVR-
1 region on E2 folding, we used a panel of human monoclonal anti-
bodies recognizing diﬀerent conformational epitopes in E2. First, we
immobilized the recombinant E1E2 onto ELISA plates by GNA-capture.
The lectin bound proteins were then probed with conformation-sensi-
tive antibodies mapped to diﬀerent domains in HCV E2. The load of
E1E2 proteins immobilized on the ELISA plates was normalized based
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Fig. 1. Construction and analysis of the expression of E1E2-Flag
glycoproteins. A. Schematic diagram of E1E2-Flag. The numbering
corresponds to the amino acid positions in the polyprotein of the
genotype 1a H77 strain. TMD – trans-membrane domain; HVR-1 –
hypervariable region 1. B. Western blot detection of E2 wt and
E2–Flag protein expression in 293T cells 24 h after transfection.
Detection using anti-E2 AP33 (left column) or anti-Flag M2 (right
column) mAbs, followed by anti-mouse IgG AP conjugate and NBT/
BCIP substrates. Mock-transfected 293T lysates were used as a ne-
gative control. Loaded amounts were normalized for total protein
content. C. Detection of gt1a E2 wt and E2-Flag proteins by im-
munohistochemical staining in ﬁxed 293T cells. 48 hrs post trans-
fection with either E1E2 wt or E1E2–Flag expression plasmids, the
cells were ﬁxed and probed with anti-E2 AP33 or anti-Flag M2
mAbs. Mock transfected HEK cells were used as a negative control.
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on the reactivity with the higly cross-reactive, slightly conformation-
sensitive (Potter et al., 2012) anti-E2 AP33 and anti-Flag mAbs (Fig. 3.
C.).
We did not observe a decreased binding of conformation sensitive
mAbs to the Flag modiﬁed E2. All tested mAbs bound Flag tag mutants
with aﬃnity similar to that observed for wild type proteins, indicating
correct conformation of E1E2-Flag recombinant proteins. Consistent
with previously published report by (Owsianka et al., 2008), one of the
conformation sensitive antibodies, namely CBH-2, failed to recognize
either the wt or the Flag-modiﬁed E2 from HCV genotype 1a (H77c).
However, all other antibodies used in this assay readily detected our
recombinant proteins.
2.6. The E1E2-Flag antigens are immunogenic in mice and induce cross-
reactive polyclonal antibodies
The puriﬁed E1E2-Flag glycoproteins were used as antigens for
mouse immunization. Three groups of six female, 5–6 weeks of age
pathogen-free C57BL/6 mice per group were intraperitoneally injected
with 5 μg E1E2-Flag per animal as shown on Fig. 4. A.
The total blood was collected from the heart of each animal
(terminal bleed) and the serum was isolated by centrifugation. Few of
the animals had ﬂuid retention in the abdomen, which was also col-
lected. The polyclonal sera were analyzed for their ability to recognize
the immunizing antigens as well as for their cross-reactivity against
antigens from diﬀerent HCV genotypes.
First, the humoral responses induced by vaccination with E1E2-Flag
proteins were quantiﬁed. The relative antibody titer of each serum was
estimated by GNA-capture ELISA against the homologous immunizing
antigen (Fig. 4. B.). All tested immunogens were able to induce high
antibody responses in the vaccinated animals. We detected higher
median titers for genotype 1a (10.9 × 104) and gt1b (9.84 × 104) E1E2
immunogens, in comparison to the gt2a (1.64 × 104) E1E2 immunogen
(p=0.01).
Next, we examined the cross-reactivity of the induced antibodies
against E1E2 glycoproteins derived from heterologous HCV genotypes.
The obtaining of humoral cross-reactivity is a challenging task, due to
the high genetic diversity of HCV. The GNA-capture ELISA experiments
indicated that the immunizations induced both homologous and het-
erologous antibody responses. The GNA-capture ELISA experiments, in
which E1E2 glycoproteins from diﬀerent genotypes were used as anti-
gens, conﬁrmed that the analyzed sera successfully recognized HCV
genotypes 1a (UKN 1a.12.18), 2b (UKN 2b1.1), 4 (UKN 4.21.16) and 6
(UKN 6.5.34) (Fig. 4. C.). We observed induction of broad and strongly
cross-reactive antibody responses in case of gt1a E1E2-Flag antigen and
lower in case of gt1b. Antibodies induced by the gt2a E1E2-Flag im-
munogen had lowest cross-reactivity; in particular against E1E2 com-
plexes from genotypes 4 and 6, while homologous antigen binding was
high.
2.7. The E1E2-Flag polyclonal mouse sera neutralize HCV entry in vitro
The sera were furthermore tested for their ability to block the entry
of cell-cultured hepatitis C virus (HCVcc) into hepatocytes by in vitro
neutralization assay. To assess neutralizing activity, pre-immune
(preIM) and terminal bleed sera were tested against gt1a (H77/JFH1
chimera) and 2a (JFH1) cell-cultured HCV viruses. 50 focus-forming
units (FFU) of H77/JFH1/HQL or JFH-AM71 – cell-culture adapted,
high-titer producing viruses (data not shown), were pre-incubated with
the appropriate inhibitory serum or control antibody prior to infection.
For the accurate quantitation of HCV replication in cell culture, we used
the cell-based secreted alkaline phosphatase (SEAP) reporter assay. This
assay is based on the Huh7-J20 reporter cell line, which stably ex-
presses the fusion protein enhanced green ﬂuorescent protein (EGFP)
fused in-frame to the SEAP via a recognition sequence of the viral NS3/
4A serine protease. Upon virus infection, SEAP is cleaved by the HCV
NS3/4A protease leading to its release into the culture medium (Iro
et al., 2009).
As expected, the 1a-Flag and 1b-Flag sera neutralized the 1a HCVcc
chimeric virus more eﬃciently – with median values of 66 and 64 per
cent respectively, versus the 2a-Flag with a median value of 47%
neutralization (Fig. 5). The contrary was observed for the JFH1 virus,
which was neutralized stronger by the 2a-Flag sera (median of 58%)
and less eﬃciently by 1a- (50%) and 1b-Flag (38%), with p values of
0.02 and 0.01, respectively. The median value for gt1b was decreased
by one individual mouse serum, which presented no neutralization
activity. In comparison, the anti-E2 mAb AP33 neutralized HCVcc by
over 80% and the preIM serum had a 22–25% unspeciﬁc blocking of
entry.
3. Discussion
In the present study, three Flag-tagged mutants of HCV E1E2 from
genotypes 1a, 1b and 2a were generated, with the in-frame Flag in-
sertion at position 409 in the HVR-1 of E2. We have previously shown
(Rychlowska et al., 2011) that this place tolerates small insertions
without major defects in E2 from gt1a (strain H). Here we conﬁrm this
phenomenon is not restricted to the H77 clone alone.
The insertion site was diﬀerent than in other reports where Flag
insertions were mostly replacing HVR-1 (Cocquerel et al., 2003;
Takahashi et al., 2010) or added to the N-terminus of E2 via variety of
linkers (Merz et al., 2011; Prentoe and Bukh, 2011). The choice of Flag
placement is essential for the preservation of the E2 regions crucial for
virus entry to host cells and for E2 immunogenicity (Vasiliauskaite
et al., 2017). The E1E2-Flag proteins were eﬃciently expressed as
shown by Western blotting and in situ immunostaining of E1E2 wt and
Flag expressed in 293T cells. Finally, we standardized the procedure for
production and puriﬁcation of E1E2-Flag proteins. Using aﬃnity-based
chromatography Flag-tagged E1E2 were puriﬁed from cellular protein
contaminants by over a 1000-fold as measured by protein determina-
tions of the puriﬁcation fractions. Using the M2 resin, around 30% of
the input of bound protein could be eluted in batch puriﬁcation.
Furthermore, we could show the Flag mutants retained their au-
thentic biological properties, as E2 was able to form a heterodimer with
E1. Moreover, the recombinant E1E2 were able to bind to the cellular
receptor CD81, which is a crucial factor in the HCV life cycle. However,
as reported earlier by (Roccasecca et al., 2003), a substantial diﬀerence
in binding eﬃciency between the three genotypes was observed, with
Fig. 2. Puriﬁcation of gt1a E1E2-Flag from transfected 293T cells. 48 hrs post
transfection with gt1a E1E2-Flag expression plasmid, the cells were lysed and
incubated with the M2 anti-Flag agarose. The eluted fraction was analyzed by
A. Coomassie-stained SDS-PAGE (the E2 and E1 bands are indicated by red
frames; a ~ 50 kDa band of the H chain of the anti-Flag antibody is visible as the
only impurity) and by B. Western blot using the anti-E2 AP33 and the anti-E1
A4 mAbs.
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proteins derived from gt1b and 2a showing signiﬁcantly lower binding
than the gt1a protein. Interestingly, our 1b and 2a Flag mutants bound
CD81 stronger than their homologous wild types, indicating a possible
conformational modiﬁcation in E2, leading to a better presentation of
the region immediately succeeding the HVR-1.
A panel of human monoclonal conformation-sensitive Abs (a kind
gift from S. K. Foung), previously described by (Hadlock et al., 2000)
and (Owsianka et al., 2008) was used for the analysis of correct folding
and conformational epitopes of the recombinant E1E2. These mAbs
recognize diﬀerent parts of the E2 structure and are phylogenetically
grouped in three groups, each binding to a diﬀerent domain in E2 (Keck
et al., 2004). The CBH-4 G, CBH-7, HC-1 and HC-11 mAbs recognized
the Flagged E1E2 from all three genotypes with similar aﬃnity as
compared to the wt. The CBH-2 mAb, recognized gt1b and 2a but not
1a, which is consistent with previous report (Owsianka et al., 2008),
where this antibody failed to bind to the H77 clone.
The previous studies used the Flag tag for puriﬁcation of viral
particles of cell-cultured HCV (HCVcc), however no immunological
studies were performed. We used puriﬁed gt1a, 1b and 2a E1E2-Flag
proteins for mouse immunizations and they elicited strong immune
responses, raising high titers of antibodies after introducing as little as
5 µg protein per animal. In GNA-capture ELISA, the mouse polyclonal
sera reacted with the E1E2-Flag immunogen as well as to the homo-
logous wild type. The median antibody titer values were as high as 10.9
× 104 for gt1a-Flag and 9.84 × 104 for gt1b, while in the 2a-Flag group
were tenfold lower (1.64 × 104).
Due to the genetic diversity of HCV it was important to check the
cross-genotypic reactivity of the sera. In GNA-capture ELISA, we could
show that 1a- and 1b-Flag recognize best E1E2 from gt4 (UKN 4.21.16)
and 6 (UKN 6.5.34), while for gt2b (UKN 2b1.1) the strongest reaction
Fig. 3. Functional and structural analyses of
E1E2-Flag proteins. A. E1 glycoprotein co-im-
munoprecipitates with E2. 293T cells tran-
siently expressing wt and E1E2-Flag were me-
tabolically radiolabeled with [35S]-Met and
lysed 48 hrs post transfection. The proteins
were immunoprecipitated with the anti-E2
AP33 mAb, separated on 12% SDS-PAGE
(under reducing and non-reducing conditions)
and detected by radiography. B. Binding of
E1E2-Flag to CD81 tested by pull-down assay.
GST-hCD81-LEL was bound to glutathione
agarose, the batch was divided into aliquot
parts and incubated with lysates of 293T cell
expressing HCV E1E2. GST bound to glu-
tathione agarose was used as a negative con-
trol. The samples were resolved on 12% SDS-
PAGE gel and detected with AP33 mAb.
Asterisks indicate the position of E2. C.
Analysis of conformational epitopes of HCV
E1E2-Flag. Lectin-bound E1E2 complexes from
transfected 293T cell lysates were probed with
a panel of conformation-sensitive anti-E2 an-
tibodies. An irrelevant isotype control hmAb
RO4 and the slightly conformation-sensitive
anti-E2 mAb AP33 were used as negative and
positive controls, respectively. Bars represent
the mean values obtained from triplicate ex-
periments; standard deviation of the readings
is indicated.
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was detected using gt2a-Flag. Overall, the best cross-reactivity was
observed after immunizing with E1E2-Flag from genotype 1a. In
Western blot under reducing conditions, reactions were either very
weak or absent (data not shown), which when compared to the results
from the ELISA experiments suggests the presence of conformationally
sensitive antibodies in the sera.
It has been shown that spontaneous resolution of HCV infection is
associated with potent and long-lasting T-cell responses. Moreover,
early appearance of broadly neutralizing antibody responses leads to
successful clearance of infection (Osburn et al., 2014; Pestka et al.,
2007). However, recent approaches to induce virus-speciﬁc CD8 T-cells
with vectored vaccines encoding non-structural HCV proteins failed to
suppress viral load in chronically infected humans (Kelly et al., 2016)
and chimpanzees (Callendret et al., 2014). In fact, meta-analysis study
of HCV experimental vaccinations in chimpanzees demonstrated that
vaccine formulations containing structural proteins, were associated
with more signiﬁcant protective immune responses than vaccines based
solely on non-structural proteins (Dahari et al., 2010). To date, HCV
structural E1 and E2 proteins have been tested as immunogens in
variety of modalities including virus-like particles (Czarnota et al.,
2016; Garrone et al., 2011), recombinant proteins (Freedman et al.,
2017; Grzyb et al., 2016; Logan et al., 2017) and prime-boost regimens
with the use of viral vectors (Chmielewska et al., 2014; Reyes-del Valle
et al., 2012). These diﬀerent strategies were able to raise high-titer
cross-neutralizing antibody responses in animals. The most advanced
trial based on E1E2 complex puriﬁed from CHO cells induced broadly
cross-neutralizing antibodies in animals and humans in phase I clinical
trials (Wong et al., 2014).
Finally, we investigated the neutralization potential of the poly-
clonal sera. Most mice sera inhibited HCVcc viral entry by 45–65% for
the gt1a H77/JFH chimera and 38–58% for the gt2a JFH1 virus.
Recently, vaccines eliciting neutralizing antibodies to structural epi-
topes have been evaluated as protective against HIV (Jardine et al.,
2013), respiratory syncytial virus (RSV) (Correia et al., 2014) and
Fig. 4. Immunological analyses of E1E2-Flag
mouse sera, A. Immunization scheme. C57BL/6
mice were primed at day 0 with full length
E1E2-Flag (gt1a, 1b or 2a), and boosted with
the same antigen at weeks 2, 5 and 8. The
terminal bleed was at week 10. B.
Quantiﬁcation of humoral responses induced
by vaccination with E1E2-Flag proteins. Lectin-
bound gt1a, 1b or 2a E1E2-Flag immunogens
were probed with the corresponding homo-
logous E1E2-Flag sera in three-step serial di-
lutions (starting from 1:500, up to 1:106).
Absorbance was measured at 450 nm. Each dot
on the plot represents one animal (■ - 1a-Flag,
♦ - 1b-Flag, • - 2a-Flag). The antibody titer was
estimated as the serum concentration, at which
binding was 2 times higher than the pre-im-
mune (preIM) control. The horizontal bars re-
present the median value for each group. C.
Cross-reactivity of mice sera against selected
HCV genotypes. Lectin-bound E1E2 complexes
from 293T cell lysates, transfected with gt1a
(the heterologous strain UKN 1a.12.18), gt2b
(UKN 2b1.1), gt4 (UKN 4.21.16) or gt6 (UKN
6.5.34) were probed with each of the E1E2-
Flag sera, followed by anti-mouse IgG–HRP
conjugate and TMB substrate. Absorbance was
measured at 450 nm. The anti-E2 AP33 mAb
was used as a positive and the anti-Flag M2 and
preimmune (preIM) serum as negative con-
trols, respectively. Mock transfected 293T cell
lysates (no env) were used for the estimation of
background signal. Error bars represent stan-
dard deviations of the individual mouse re-
sponses.
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inﬂuenza (Mallajosyula et al., 2014; Yassine et al., 2015). This further
supports the notion that a universal vaccine against HCV should include
components inducing strong humoral responses to conserved structural
epitopes and encourages the search for ideal E1E2 immunogen mod-
alities.
The E1E2-Flag mutants reported here could turn out to be important
candidates for vaccine antigens. Furthermore, they can be used as au-
thentic counterparts of native proteins in structural studies, diagnostic
tests or for the generation of new potent neutralizing monoclonal an-
tibodies.
4. Methods
4.1. Antibodies
The mouse anti-E2 AP33 has been described previously (Owsianka
et al., 2005). The anti-E1 A4 (Dubuisson et al., 1994) mAbs was gen-
erously provided by J. Dubuisson. The human anti-E2 mAbs CBH-2,
CBH-4B, CBH-5, CBH-7 and HC-11 (Hadlock et al., 2000; Keck et al.,
2004) have been a kind gift from S. K. Foung. Anti-Flag M2 mAb was
purchased from Sigma-Aldrich.
4.2. Cell lines
Human epithelial kidney (HEK) 293T cells and human hepatoma
Huh-7 and Huh7-J20 (Iro et al., 2009) cells were propagated in Dul-
becco’s modiﬁed essential medium (DMEM) supplemented with 10%
fetal bovine serum, in standard cell culture conditions.
4.3. Construction of E1E2-Flag expression plasmids
The plasmid encoding HCV genotype 1a strain H77c (Choo et al.,
1989) E1E2 (GenBank accession number AF011751) was previously
described by (Yanagi et al., 1997), while the two patient-derived clones
– UKN 1b.12.6 (AY734975) and UKN 2a.2.4 (AY734979) (Lavillette
et al., 2005), were obtained from the laboratory of J. Ball, University of
Nottingham, UK. For genotypes 1a and 1b, the Flag sequence was fused
in-frame to the E2 sequence by classic insertion PCR. In brief, using the
H77 and UKN1b as templates, a PCR was performed using the following
primers: 1a_fwd 5′-GGCGCCAAGGACTACAAGGACGATGACGATAAAC
AGAACATCCAACTGATC-3′ and 1a_rev 5′-CGTATCATTTGCACCCCAG
CTGTAGGTAGGCGCGCCCGACCTGTC-3′; and 1b_fwd 5′-CTTTAGATC
TGGACCGTCTGACTACAAGGACGATGACGATAAACAGAAGATCCAACT
TGTGAA-3′ and 1b_rev 5′-CATCCATGTACAGCCGAACC-3′. The E1E2
vector and the PCR products were cut with EheI-AscI and BglII-
Bsp1407l, respectively, and ligated.
The cloning strategy for gt2a was based on a three-step assembly
PCR, due to its characteristic sequence. In the ﬁrst step, using primers
2a_1fwd 5′-GGAGCGTGGGCTAAGGTCATC-3′ and 2a_1rev 5′-TACAAG
TCACATCCACGCTCTCTGATGTTCCTGCTACTGCTATTT-3′ and the
UKN 2a2.4 as a matrix, a 355 bp product (PCR1) was ampliﬁed, which
had a SmaI restriction site near its 5′ end and the Flag sequence at its 3′
end. Then using primers 2a_2fwd 5′-GACTACAAGGACGATGACGATA
AACAAAACATCCAGCTTATCAAC-3′ and 2a_2rev 5′-TCGTGTGCCGGC
GGTGTTCCC-3′, a 492 bp product was obtained, containing Flag at its
5′ and XcmI restriction site near its 3′ end (PCR2). Finally, PCR1 and
PCR2 were assembled into an 823 bp product using primers 2a_1fwd
and 2a_2rev (PCR3). The PCR3 fragment was digested with SmaI and
XcmI restriction enzymes, ligated to UKN 2a2.4 and sequenced. The
sequencing conﬁrmed presence of Flag and absence of any additional
mutations. The new constructs were further referred to as E1E2-Flag.
4.4. Expression and puriﬁcation of E1E2-Flag
293T cells were transfected with the E1E2-Flag plasmids using the
CaPO4 method. 48hrs after transfection the cells were lysed using the
mild buﬀer and protein expression was analyzed via Western blotting.
The binding was performed in a batch format – 1ml of cell lysate was
added to 50 µl washed resin. For the negative control, 1 ml of lysate
from cells transfected with GFP was used. All samples and controls were
agitated gently on a roller shaker for 2 h at RT. All unbound protein was
removed by washing the resin three times with 1ml TBS. After the ﬁnal
wash, all the supernatant was removed and the bound Flag-tagged
protein eluted from the agarose by incubation with 0.5ml of 0.1M
glycine-HCl, pH 3.5 buﬀer. The test tubes were incubated for 5min at
room temperature with gentle shaking. The agarose was not left in this
low pH buﬀer for more than 10min in order not to dissociate the M2
mAb. The probes were centrifuged for 30 s at 7000×g and the su-
pernatants were immediately transferred to fresh Eppendorf test tubes
containing 10 µl of 1M Tris HCl, pH 8.8. For immediate use the su-
pernatants were stored on ice or alternatively frozen at−20 °C for long-
term storage.
Fig. 5. Neutralization of HCVcc by the E1E2-Flag polyclonal mouse sera. Huh-7-J20 cells were infected with 50 FFU of virus, pre-incubated with the appropriate
inhibitory or control antibody (H77/JFH1/HQL chimera – left panel; JFH1-AM71 – right panel). After 48 hrs, the infectivity was determined by measurement of the
SEAP activity released into the medium. Each dot on the plot represents one animal (■ - 1a-Flag, ♦ - 1b-Flag, • - 2a-Flag). The anti-E2 AP33 mAb and preIM serum
were used as positive and negative controls, respectively. The horizontal bars represent the median value for each group.
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4.5. In situ immunocytochemical staining
E1E2 transfected 293T cells monolayers were washed with PBS,
frozen at 70 °C for 15min, and ﬁxed with 4% paraformaldehyde. Cells
were probed with anti-E2 mAb AP33 diluted 1:1000 in PBS with 5%
fetal bovine serum (FBS), 0.1% sodium azide, 1% Tween-80 or anti-Flag
M2 mAb diluted 1:500. Secondary HRP-conjugated anti-mouse anti-
body (Santa Cruz) diluted 1:2000 in PBS with 5% FBS, 1% Tween-80
was used. The reaction was developed with the Nova-RED substrate kit
(Vector Laboratories).
4.6. GNA-capture ELISA
Detection of E1E2 by ELISA was performed as described by (Tarr
et al., 2007). Brieﬂy, 96-well plates coated with GNA lectin were used
to capture glycoproteins from lysates of HEK 293T cells transiently
expressing wt or mutated E1E2, prepared as described above. Lysate
from mock-transfected cells served as a negative control. Bound pro-
teins were detected by using appropriate antibodies followed by anti-
species IgG–HRP conjugate and TMB substrate (Sigma-Aldrich).
4.7. E1E2 co-immunoprecipitation
293T cells, transiently expressing E1E2 wt or E1E2-Flag, were me-
tabolically radiolabeled with [35S]-Met and lysed 48 h post transfection,
proteins were immunoprecipitated with anti-E2 AP33 mAb, separated
on 12% SDS-PAGE (reducing and non-reducing) and detected by
radiography.
4.8. CD81-binding assay
CD81 binding was performed as previously described by (Tarr et al.,
2007). In brief, Glutathione Sepharose beads were ﬁrst coated with
recombinant GST-hCD81-LEL for 2 h at 4 °C and washed twice in
PBS–1% Triton X-100. They were then divided into aliquot parts and
incubated overnight with lysates from HEK 293T cells expressing HCV
E1E2 wt or Flagged, as well as with mock control. The samples were
washed 4x in PBS–1% Triton X-100 and once in water before addition
of Laemmli buﬀer and resolved on 12% SDS-PAGE gel. As a negative
control, GST bound to glutathione Sepharose was used. E2 was detected
with AP33 mAb.
4.9. Animals and vaccinations
Animal experiments were approved by local animal ethics com-
mittees and were performed in accordance with national and interna-
tional laws and policies. Groups of six female 5–6 weeks of age C57BL/6
mice were vaccinated intraperitoneally with E1E2-Flag (5 μg per
mouse). Recombinant protein was formulated by being mixed 1:1 with
incomplete Freund’s adjuvant (IFA) immediately before immunization.
Blood samples were collected by tail-bleeding and total blood by car-
diac puncture. All in vivo procedures were performed under deep an-
esthesia.
4.10. HCVcc neutralization
Antibody inhibition assays were performed using Huh7-J20 cells,
and virus infectivity levels were determined by secreted alkaline
phosphatase (SEAP) reporter assay, as described previously (Iro et al.,
2009). Brieﬂy, Huh7-J20 cells were plated out at a density of 3×103
per well in a 96-well plate.∼50 FFU of virus was pre-incubated at 37 °C
for 1 h with the appropriate inhibitory or control antibody prior to in-
fecting cells. At 3 h post infection, the inoculum was replaced with fresh
medium and incubated for 48 h. The infectivity was determined by
measurement of the SEAP activity released into the medium.
In this assay, H77/JFH1/HQL (HCV1a) and JFH1-AM71 (HCV2a)
viruses were used. The adaptive mutations in HQL, (Y835H, K1402Q
and V2440L) and AM71, increased the viral titers up to 1× 106
CCID50/ml (data not shown). The analyzed sera were diluted 1:50, the
control anti-E2 AP33 antibody was used in inhibitory concentration of
100 μg/ml. Controls included non-infected cells and cells infected with
mock treated viruses (no antibodies).
4.11. Statistical analysis
Statistical analysis and graphs were made using Prism 7 for OS X
software (GraphPad). A 2-tailed t-test (paired or unpaired as appro-
priate) was used to determine if there were signiﬁcant diﬀerences.
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